Details of a Researcher - Tsuchiya, Masami

Papers - Tsuchiya, Masami

Division display 21 - 40 of about 65 ／ All the affair displays >>

External Validation and Update of the Risk Prediction Model for Denosumab-Induced Hypocalcemia Developed From a Hospital-Based Administrative Database.

Keisuke Ikegami, Shungo Imai, Osamu Yasumuro, Masami Tsuchiya, Naomi Henmi, Mariko Suzuki, Katsuhisa Hayashi, Chisato Miura, Haruna Abe, Hayato Kizaki, Ryohkan Funakoshi, Yasunori Sato, Satoko Hori

JCO clinical cancer informatics 8 e2400078 2024.07

ISSN 2473-4276

PURPOSE: Denosumab is used to treat patients with bone metastasis from solid tumors, but sometimes causes severe hypocalcemia, so careful clinical management is important. This study aims to externally validate our previously developed risk prediction model for denosumab-induced hypocalcemia by using data from two facilities with different characteristics in Japan and to develop an updated model with improved performance and generalizability. METHODS: In the external validation, retrospective data of Kameda General Hospital (KGH) and Miyagi Cancer Center (MCC) between June 2013 and June 2022 were used and receiver operating characteristic (ROC)-AUC was mainly evaluated. A scoring-based updated model was developed using the same data set from a hospital-based administrative database as previously employed. Selection of variables related to prediction of hypocalcemia was based on the results of external validation. RESULTS: For the external validation, data from 235 KGH patients and 224 MCC patients were collected. ROC-AUC values in the original model were 0.879 and 0.774, respectively. The updated model consisting of clinical laboratory tests (calcium, albumin, and alkaline phosphatase) afforded similar ROC-AUC values in the two facilities (KGH, 0.837; MCC, 0.856). CONCLUSION: We developed an updated risk prediction model for denosumab-induced hypocalcemia with small interfacility differences. Our results indicate the importance of using data from plural facilities with different characteristics in the external validation of generalized prediction models and may be generally relevant to the clinical application of risk prediction models. Our findings are expected to contribute to improved management of bone metastasis treatment.

Access to Document (DOI)

Association Between Meteorological Elements and Hand-Foot Syndrome in Patients on Capecitabine-Containing Chemotherapy: An Observational Exploratory Study

Takashi Uchida, Masami Tsuchiya, Katsuhisa Hayashi, Gen Iwasashi, Kyoko Inooka

Japanese Journal of Pharmaceutical Health Care and Sciences (Japanese Society of Pharmaceutical Health Care and Sciences) 50 ( 6 ) 303 - 311 2024.06

Accepted, ISSN 1346-342X

Access to Document (DOI)

The emerging emetogenicity of trifluridine/tipiracil (TAS‑102) from patient self-reporting: a multicenter, prospective, observational study.

Hironori Fujii, Masami Tsuchiya, Daichi Watanabe, Ryo Otsuka, Daisuke Hirate, Katsuyuki Takahashi, Makiko Go, Toshihiro Kudo, Kazuhiro Shimomura, Yosuke Ando, Shinya Tani, Takao Takahashi, Katsuhisa Hayashi, Miki Chin, Naomi Matsunami, Masaya Takahashi, Akiko Hasegawa, Takashi Uchida, Hironobu Hashimoto, Akiko Kubo, Nobuhisa Matsuhashi, Akio Suzuki, Junichi Nishimura, Naoki Inui, Hirotoshi Iihara

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 32 ( 5 ) 291 - 291 2024.04

BACKGROUND: Trifluridine/tipiracil (TAS-102) is an oral anticancer drug with adequate efficacy in unresectable colorectal cancer, but frequently also induces chemotherapy-induced nausea and vomiting (CINV). To investigate the occurrence of CINV and antiemetic therapy in patients with colorectal cancer treated with TAS-102 (JASCC-CINV 2001). METHODS: We conducted a multicenter, prospective, observational study in patients with colorectal cancer who received TAS-102 without dose reduction for the first time. Primary endpoint was the incidence of vomiting during the overall period. Secondary endpoints were the incidence of nausea, significant nausea, anorexia, other adverse events (constipation, diarrhea, insomnia, fatigue, dysgeusia) and patient satisfaction. Patient diaries were used for primary and secondary endpoints. All adverse events were subjectively assessed using PRO-CTCAE ver 1.0. and CTCAE ver 5.0. RESULTS: Data from 100 of the 119 enrolled patients were analyzed. The incidence of vomiting, nausea, and significant nausea was 13%, 67%, and 36%, respectively. The incidence of vomiting in patients with and without prophylactic antiemetic therapy were 20.8% and 10.5%, respectively. Prophylactic antiemetics were given to 24% of patients, of whom 70% received D2 antagonists. Multivariate Cox proportional hazards analysis showed that experience of CINV in previous treatment tended to be associated with vomiting (hazard ratio [HR]: 7.13, 95% confidence interval [CI]: 0.87-58.5, P = 0.07), whereas prophylactic antiemetic administration was not (HR: 1.61, 95 CI: 0.50-5.21, P = 0.43). With regard to patient satisfaction, the proportion of patients who were "very satisfied," "satisfied," "slightly satisfied" or "somewhat satisfied" was 81.8%. CONCLUSIONS: The low incidence of vomiting and high patient satisfaction suggest that TAS-102 does not require the use of uniform prophylactic antiemetic treatments. However, patients with the experience of CINV in previous treatment might require prophylactic antiemetic treatment.

Access to Document (DOI)

Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer.

Kaori Takahashi, Ryuji Uozumi, Toru Mukohara, Tetsu Hayashida, Midori Iwabe, Hirotoshi Iihara, Kanako Kusuhara-Mamishin, Yuko Kitagawa, Masami Tsuchiya, Mika Kitahora, Aiko Nagayama, Shinkichi Kosaka, Yoshimi Asano-Niwa, Tomoko Seki, Koji Ohnuki, Akio Suzuki, Fumiko Ono, Manabu Futamura, Hitoshi Kawazoe, Tomonori Nakamura

The oncologist 29 ( 6 ) e741 - e749 2024.02

ISSN 1083-7159

BACKGROUND: Proton pump inhibitors (PPIs) reduce the bioavailability of several anticancer drugs. The impact of PPIs co-administered with cyclin-dependent kinase 4 and 6 inhibitors is controversial. We aimed to clarify whether the concomitant use of PPIs impacts palbociclib and abemaciclib effectiveness in breast cancer treatment. PATIENTS AND METHODS: This multicenter, retrospective, observational study, conducted across 4 medical institutions in Japan, consecutively included patients with endocrine-resistant metastatic breast cancer, receiving palbociclib or abemaciclib between December 2017 and August 2022. Propensity score-matched analyses were performed. Treatment efficacy and safety with and without PPIs were compared. Progression-free survival and overall survival were estimated using the Kaplan-Meier method and compared using a log-rank test. A Cox proportional hazards model was used to estimate the hazard ratio. RESULTS: The study included 240 patients. After 1:1 matching, 112 patients were treated with and without PPIs. The median progression-free survival period was 1.2 years in the PPI group and 1.3 years in the non-PPI group (hazard ratio, 1.19; 95% CI, 0.70-2.02). The median overall survival period was 3.6 years in the PPI group, whereas it was not reached in the non-PPI group (hazard ratio, 1.23; 95% CI, 0.61-2.47). Consistent results were obtained for subgroups receiving palbociclib (n = 177) and abemaciclib (n = 63) without propensity score matching. Adverse event incidence and severity were similar in both groups. CONCLUSION: The effectiveness of cyclin-dependent kinase 4/6 inhibitors is unlikely to be affected by concomitant PPI use. Future prospective pharmacokinetic studies are warranted.

Access to Document (DOI)

添付文書で妊婦に対して禁忌に設定されている医薬品の特定と国際比較

酒井隆全, 佐藤ユリ, 畠山史朗, 菊池大輔, 土屋雅美, 近藤悠希, 佐藤泉美, 岡田裕子, 小原拓

医薬品情報学 ((一社)日本医薬品情報学会) 25 ( 4 ) 211 - 219 2024.02

ISSN 1345-1464

日本の添付文書で妊婦禁忌と記載された医薬品を特定し、海外における妊娠期の医薬品安全性分類と比較、評価した。2022年4月時点で薬価収載されている医療用医薬品19022医薬品のうち、妊娠禁忌の医薬品は4111医薬品(21.6%)であり、妊娠時期を限定せずに禁忌となっているものが9割以上を占めていた。薬効分類別では循環器用薬に次いでその他の代謝性医薬品が多く、the Australian categories for prescribing medicines in pregnancy(TGA分類)で禁忌に相当するXに分類された成分は16成分(4.3%)のみであった。医療関係者は添付文書における妊婦禁忌の留意点を適切に認識し、妊婦における医薬品の安全性情報を十分に評価した上で、使用可否について慎重に判断するべきであることが示唆された。

Evaluation of hospital pharmacists’ activities using additional reimbursement for infection prevention as an indicator in small and medium-sized hospitals

Yuichi Tasaka, Takeshi Uchikura, Shiro Hatakeyama, Daisuke Kikuchi, Masami Tsuchiya, Ryohkan Funakoshi, Taku Obara

Journal of Pharmaceutical Health Care and Sciences (Springer Science and Business Media LLC) 10 ( 1 ) 6 - 6 2024.01

Abstract

Background

Hospitals in Japan established the healthcare delivery system from FY 2018 to 2021 by acquiring an additional reimbursement for infection prevention (ARIP) of category 1 or 2. However, research on outcomes of ARIP applications related to the practice of hospital pharmacists is scarce.

Methods

This study assessed the activities performed by hospital pharmacists in hospitals with 100 to 299 beds, using ARIP acquirement as an indicator, using data from an annual questionnaire survey conducted in 2020 by the Japanese Society of Hospital Pharmacists on the status of hospital pharmacy departments. Out of the survey items, this study used those related to hospital functions, number of beds, number of pharmacists, whether the hospital is included in the diagnosis procedure combination (DPC) system, average length of stay, and nature of work being performed in the analysis. The relationship between the number of beds per pharmacist and state of implementation of pharmacist services or the average length of hospital stay was considered uncorrelated when the absolute value of the correlation coefficient was within 0–0.2, whereas the relationship was considered to have a weak, moderate, or strong correlation when the absolute value ranged at 0.2–0.4, 0.4–0.7, or 0.7–1, respectively.

Results

Responses were received from 3612 (recovery rate: 43.6%) hospitals. Of these, 210 hospitals meeting the criteria for ARIP 1 with 100–299 beds, and 245 hospitals meeting the criteria for ARIP 2 with 100–299 beds, were included in our analysis. There was a significant difference in the number of pharmacists, with a larger number in ARIP 1 hospitals. For the pharmacist services, significant differences were observed, with a more frequency in ARIP 1 hospitals in pharmaceutical management and guidance to pre-hospitalization patients, sterile drug processing of injection drugs and therapeutic drug monitoring. In DPC hospitals with ARIP 1 (173 hospitals) and 2 (105 hospitals), the average number of beds per pharmacist was 21.7 and 24.7, respectively, while the average length of stay was 14.3 and 15.4 d, respectively. Additionally, a weak negative correlation was observed between the number of pharmacist services with “Fairly well” or “Often” and the number of beds per pharmacist for both ARIP 1 (R = -0.207) and ARIP 2 (R = -0.279) DPC hospitals. Furthermore, a weak correlation (R = 0.322) between the average number of beds per pharmacist and the average length of hospital stay was observed for ARIP 2 hospitals.

Conclusions

Our results suggest that lower beds per pharmacist might lead to improved pharmacist services in 100–299 beds DPC hospitals with ARIP 1 or 2. The promotion of proactive efforts in hospital pharmacist services and fewer beds per pharmacist may relate to shorter hospital stays especially in small and medium-sized hospitals with ARIP 2 when ARIP acquisition was used as an indicator. These findings may help to accelerate the involvement of hospital pharmacists in infection control in the future.

Access to Document (DOI)

Proposal for Classifying the Emetogenicity of Oral Anticancer Agents with a Focus on PARP Inhibitors: A Prospective, Observational, Multicenter Study (JASCC-CINV 2002)

Senri Yamamoto, Masami Tsuchiya, Hirotoshi Iihara, Yoh Hayasaki, Kyoko Hori, Yasuo Kumakura, Daichi Watanabe, Hideki Sakai, Satoshi Nakagawa, Akiko Kudoh, Hajime Oishi, Nobuhiro Kado, Makiko Go, Kota Mashima, Takashi Uchida, Moeka Yasue, Akimitsu Maeda, Kimihiro Nishino, Koji Matsumoto, Shinya Sato, Yutaka Ueda, Kensuke Tomio, Katsuhisa Hayashi, Motoki Takenaka, Masahiko Mori, Hiroaki Kajiyama, Yoshimasa Bomoto, Shiro Suzuki, Takuma Ishihara, Akio Suzuki, Masakazu Abe

Journal of Cancer (Ivyspring International Publisher) 15 ( 6 ) 1487 - 1497 2024.01

ISSN 1837-9664

Access to Document (DOI)

Survey on Attitudes toward Career Visions for Hospital Pharmacists

Hitoshi Kawazoe, Masami Tsuchiya, Maki Todo, Azusa Hara, Yumiko Ohnishi, Yoichi Osato, Satoko Hori

YAKUGAKU ZASSHI (Pharmaceutical Society of Japan) 143 ( 8 ) 683 - 691 2023.08

Lead author, Accepted, ISSN 0031-6903

Access to Document (DOI)

Elucidating the Actual Utilization of Risk Management Plans (RMPs) in Hospital Pharmacy Departments

Daisuke Kikuchi, Masami Tsuchiya, Shiro Hatakeyama, Yuichi Tasaka, Takeshi Uchikura, Ryohkan Funakoshi, Taku Obara

Journal of Japanese Society of Hospital Pharmacists ((一社)日本病院薬剤師会) 59 ( 8 ) 833 - 839 2023.08

Accepted, ISSN 1341-8815

医薬品リスク管理計画(risk management plan:以下,RMP)は医薬品の適正使用推進とリスク最小化のために重要な情報である。本研究の目的は「平成30年度病院薬剤部門の現状調査」を用いて,RMPの利活用の実態を明らかにすることである。解析対象2,751施設のうちRMPを活用していたのは909施設(33.0%)であった。多変量解析の結果,病棟薬剤業務実施加算あり,患者の状態観察に基づく薬効・副作用の確認等にかなり取り組んでいる,医薬品の有効性・安全性情報の収集,管理および提供にかなり取り組んでいる,副作用等を一元管理している部門ありが,RMPの活用と正に関連しており,薬剤師1人当たりの病床数が多いことがRMPの活用と負に関連していた。本研究より,薬剤師1人当たりの病床数を低減させることによるファーマコビジランス業務の推進は,RMPの活用を介した医薬品安全使用に重要である。(著者抄録)

The prevalence of end-of-life chemotherapy and targeted therapy in Japan, assessed using a health claims database.

Masami Tsuchiya, Taku Obara, Masafumi Kikuchi, Nariyasu Mano

Cancer chemotherapy and pharmacology (Springer Science and Business Media LLC) 91 ( 6 ) 501 - 506 2023.05

ISSN 0344-5704

PURPOSE: This study aimed to investigate the current status of end-of-life chemotherapy and targeted therapy and explore the aggressiveness of end-of-life care in Japan using the DeSC database, a large administrative claims database. METHODS: We identified fatal cases of at least one cancer-related diagnosis between April 2015 and November 2020. Patients prescribed at least one anticancer drug were analyzed, and chemotherapy regimens were categorized based on the combination of concomitant anticancer drugs prescribed. RESULTS: Among 1,095,713 individuals enrolled in the National Health Insurance database, 7,300 deaths with cancer-related diagnosis were identified. Of these, 4,010 cases were identified in which at least one anticancer drug was prescribed, and 11.6% of 7,300 death had been prescribed anticancer drugs in their last 30 days of life. The most commonly used regimen was S-1 (tegafur, gimeracil, and oteracil potassium combination) monotherapy, followed by nivolumab monotherapy and nab-paclitaxel plus gemcitabine. Immune checkpoint inhibitor monotherapy was more likely prescribed to patients whose last chemotherapy dose was in the last 30 days of life (p = 0.0066, chi-squared test). CONCLUSIONS: This study provides insights into the current status of end-of-life chemotherapy and targeted therapy in Japan, using a large administrative claims database. The results of this study will inform future research on end-of-life chemotherapy and targeted therapy, and help develop strategies to improve the quality of life of patients with advanced cancer.

Access to Document (DOI)

自由単語記載形式アンケートによるJASPOスタートアップ・ブラッシュアップセミナー2021セミナー内容に関する解析

寺薗英之, 吉川直樹, 小川大介, 森理保, 土屋雅美, 牧陽介, 板垣文雄, 河原陽介, 西村佳子, 篠原佳祐, 岩本義弘, 益子寛之, 米村雅人, 内田まや子

日本臨床腫瘍薬学会雑誌 ((一社)日本臨床腫瘍薬学会) 30 423 - 423 2023.05

Congenital dermatofibrosarcoma protuberans presenting as a depressed plaque: Clinical presentation and chronology

Nakajima, Y; Fusumae, T; Hirai, I; Nakamura, Y; Mori, T; Nakayama, R; Tsuchiya, M; Hashimoto, R; Funakoshi, T

JOURNAL OF DERMATOLOGY 50 ( 4 ) E127 - E128 2023.04

ISSN 0385-2407

Access to Document (DOI)

Birth Outcomes of Anticancer Drug Prescriptions during Pregnancy: A Case Series from a Japanese Claims Database

Kentaro Tajima, Tomofumi Ishikawa, Masami Tsuchiya, Masafumi Kikuchi, Taku Obara, Nariyasu Mano

Pharmacoepidemiology 2023.01

Access to Document (DOI)

Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 Study.

Hirotoshi Iihara, Mototsugu Shimokawa, Hiroko Bando, Yoshimi Niwa, Yutaka Mizuno, Yoshihiro Kawaguchi, Mika Kitahora, Akari Murakami, Masaaki Kawai, Kazushige Ishida, Makoto Takeuchi, Kazuhiro Ishihara, Tomokazu Iyoda, Takumi Nakada, Atsuko Ogiso, Yasuyuki Kojima, Fumiyoshi Kumagai, Aya Sawa, Ryutaro Mori, Kosuke Higuchi, Tomoko Furuta, Yoshiaki Kamei, Masami Tsuchiya, Azusa Terasaki, Senri Yamamoto, Mai Kitazawa, Mai Okazaki, Akio Suzuki, Manabu Futamura

Journal of Cancer 14 ( 14 ) 2644 - 2654 2023

Background: Trastuzumab deruxtecan is classified as an anticancer agent that poses a moderate emetic risk in the international guidelines for antiemetic therapy. The guidelines recommend emesis prophylaxis using a two-drug combination therapy comprising a 5-hydroxytryptamine-3 receptor antagonist (5-HT3RA) and dexamethasone (DEX). However, the high incidence of nausea and vomiting associated with trastuzumab deruxtecan is problematic. The National Comprehensive Cancer Network guideline version 1.2023 classified trastuzumab deruxtecan as having a high risk of emesis and changed its recommendation to a triplet regimen including a neurokinin-1 receptor antagonist (NK1RA). However, the emetogenic potential of trastuzumab-deruxtecan and the optimal antiemetic prophylaxis are controversial. Hence, this exploratory phase 2 study aimed to assess the efficacy and safety of treatment comprising 5-HT3RA and DEX with or without a NK1RA in preventing trastuzumab deruxtecan-induced nausea and vomiting. Methods: We conducted an open-label and randomized exploratory phase 2 study at 14 centers in Japan. Patients with breast cancer who were scheduled to receive trastuzumab deruxtecan were enrolled in this study. The patients were randomly assigned to receive granisetron and DEX (arm GD) or granisetron, DEX, and aprepitant (fosaprepitant; arm GDA). The primary endpoint was complete response (CR; no emesis or no rescue therapy) during the overall phase (120 h after the start of trastuzumab deruxtecan). Results: Between September 2020 and March 2023, 40 patients were randomly assigned to the GD (n = 19) or GDA (n = 21) arm. In the GDA arm, one patient who did not complete the use of the rescue medication listed in the diary was excluded from the efficacy analysis, which included the use of rescue medication. The CR rates during the overall phase were 36.8% and 70.0% in the GD and GDA arms, respectively (odds ratio 0.1334; 95% confidence interval [CI]: 0.0232-0.7672; P = 0.0190), with a difference of 33.2%. No grade 3 or 4 toxicity related to antiemetic therapy was observed. Conclusions: Patients receiving trastuzumab deruxtecan require triple therapy, including mandatory NK1RA administration.

Access to Document (DOI)

Actual status of patient information sharing among healthcare delivery facilities: a survey by the third subcommittee, committee on academic research, the Japanese society of hospital pharmacists.

Daisuke Kikuchi, Masami Tsuchiya, Shiro Hatakeyama, Yuichi Tasaka, Takeshi Uchikura, Ryohkan Funakoshi, Taku Obara

Journal of pharmaceutical health care and sciences 8 ( 1 ) 30 - 30 2022.11

BACKGROUND: Information sharing among medical professionals is important for providing quality medical care. The purpose of the present study was to elucidate the actual status of information sharing between hospitals and other healthcare delivery facilities by surveying information sharing among the pharmaceutical departments of Japanese hospitals in 2020 conducted by the Japanese Society of Hospital Pharmacists. METHODS: Responses were received from 3612 (43.6%) of the 8278 target medical institutions between May 2020 and August 2020. RESULTS: The proportions of hospitals that shared information with community pharmacies, other hospitals, and long-term nursing homes were 40.6%, 36.4%, and 27.3%, respectively. While tracing reports were the most common tool used by hospitals for information sharing with community pharmacies (54.3%), drug summaries were used for sharing information with other hospitals and long-term nursing homes (77.4% and 78.0%, respectively). The proportion of hospitals sharing information with community pharmacies and other hospitals showed a tendency to increase as the number of hospital beds increased. No relationship could be established between the number of hospital beds and the proportion of hospitals sharing information with long-term nursing homes. CONCLUSION: Information between hospitals and community pharmacies was shared primarily using tracing reports, whereas information between hospitals and other hospitals and long-term nursing homes was primarily shared via drug summaries.

Access to Document (DOI)

Using an online journal club to improve Asian speakers' comfort in using English to discuss and understand research papers written in English.

Masami Tsuchiya, Manit Saeteaw, Suphat Subongkot, Trai Tharnpanich, Jitprapa Konmun, Izumi Nasu, Yumiko Shimanuki, Toshiaki Tsuchitani, Mio Ezura, Koji Hashiguchi, Jeffrey C Bryan, Hitoshi Kawazoe

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 10781552221107548 - 10781552221107548 2022.06

ISSN 1078-1552

INTRODUCTION: This study aimed to evaluate the participants' comfort in understanding research papers written in English and discussing such research in English via an Asian online journal club. METHODS: A self-administered online survey was delivered to seven journal club meeting attendees from July 2020 to July 2021. A customer satisfaction analysis was performed to assess the association between the participants' perspectives on program logistics and satisfaction. RESULTS: The recovery rate was 37.0% (44/119). After participating in the journal club, the median scores of critical appraisal skills, knowledge and/or pharmaceutical care skills in clinical practice, and discussion skills in English (assessed using a seven-point Likert scale) improved significantly (compared to pre-participation median scores) from 4 (interquartile range [IQR]: 3-5) to 5 (IQR: 4-6), 5 (IQR: 4-5) to 5 (IQR: 5-6), and 4 (IQR: 2-5) to 5 (IQR: 3-5), respectively (P < 0.0001). The respondents also expressed great appreciation for the benefits and overall qualities of the journal club. Additionally, regarding patient care behavior after participation in the journal club, 34 (77.3%), 17 (38.6%), 16 (36.4%), and 14 (31.8%) respondents reported improvement in "drug information services," "patient assessments," "patient counseling," and "multidisciplinary rounds," respectively. Customer satisfaction analysis revealed that sharing information, mutual discussion, a shift system of presenters and co-chairs, and session duration should be improved as a matter of highest priority. CONCLUSION: The findings suggest that our program could be helpful for Asian pharmacists, pharmacy students, and faculty members of the department of pharmacy.

Access to Document (DOI)

Vonoprazan-associated nephrotoxicity: extensive real-world evidence from spontaneous adverse drug reaction reports

Masayuki Ishida, Masami Tsuchiya, Junko Naito, Hitoshi Kawazoe, Daichi Watanabe, Yujiro Nonaka, Mika Sano, Hiroyasu Sakai, Akio Suzuki, Keisuke Kumada, Hiroyuki Okura, Masahito Shimizu, Hirotoshi Iihara

Kidney International (Elsevier BV) 102 ( 3 ) 666 - 668 2022.06

ISSN 0085-2538

Access to Document (DOI)

多様な進路・働き方における薬剤師のキャリアパスに対する意識調査

土屋雅美, 河添仁, 大西友美子, 島田美樹, 堀里子

医療薬学 ((一社)日本医療薬学会) 48 ( 6 ) 249 - 258 2022.06

ISSN 1346-342X

第31回日本医療薬学会年会において開催された「薬剤師のキャリアパスに関するシンポジウム」を視聴した薬剤師65名を対象とし、職場環境やキャリアパスへの満足度に関する質問紙調査を行った。結果、職場におけるロールモデルの存在に関する満足度は全体的に低かった一方で、家族によるキャリアパス支援に関する満足度は比較的高い傾向が認められた。顧客満足度(CS)分析の手法を用い、キャリアパスに関して優先的に解決すべき課題について薬剤師はどのように考えているのか分析した結果、優先順位が最も高かったのは「教育研修体制」であり、次いで「ワーク・ライフバランス」、「研究活動」の順であった。シンポジウムの感想を自由記述してもらい、対応分析を行った結果、キャリア満足度が低い群に特徴的な語として[必要][視聴][大変][参考]などがあり、キャリア満足度が高い群に特徴的な語として[経験][研究][振り返る][現状][想像][上司][目標][違い][勉強]などがあった。

Itraconazole Contaminated with Rilmazafone in Japan: A Retrospective Analysis Using the Japanese Adverse Drug Event Report Database

Masami Tsuchiya, Taku Obara, Nariyasu Mano

Drugs - Real World Outcomes (Springer Science and Business Media {LLC}) 9 ( 3 ) 315 - 319 2022.05

ISSN 2199-1154

BACKGROUND: In early December 2020, the antifungal medication, itraconazole (ITCZ), was mistakenly contaminated with rilmazafone in Japan. Healthcare professionals reported adverse drug reaction reports associated with ITCZ and included central nervous system-depression symptoms such as dizziness, lightheadedness, loss of consciousness, and intense drowsiness. OBJECTIVE: We examined ITCZ-associated suspicious cases using the Japanese Adverse Drug Event Report (JADER) database to determine the impact of adverse drug reaction reporting on post-marketing safety measures. METHODS: Adverse drug reaction reports in which the suspicious or concomitant medication was ITCZ or fluconazole (FLCZ) were extracted from the JADER dataset. The number of adverse drug reaction reports associated with central nervous system-depression adverse drug reactions were counted, and chronological changes were compared with ITCZ and FLCZ. RESULTS: Of the 713,893 adverse drug reaction reports in the JADER database, 5048 cases were associated with ITCZ and 6007 cases with FLCZ. When ITCZ contamination occurred, the number of adverse drug reaction reports associated with ITCZ increased rapidly, while those with FLCZ did not. In addition, the proportion of central nervous system-depression adverse drug reactions increased only in the ITCZ-associated report. CONCLUSIONS: An incident of ITCZ contamination with rilmazafone was detected on the JADER retrospectively. This case highlights the importance of spontaneous adverse drug reaction reporting, even if the causal relationship between the drug and adverse drug reaction is unknown.

Access to Document (DOI)

Proton pump inhibitors affect capecitabine efficacy in patients with stage II-III colorectal cancer: a multicenter retrospective study.

Yoshiko Kitazume, Hitoshi Kawazoe, Ryuji Uozumi, Tomoe Yoshizawa, Hirotoshi Iihara, Hironori Fujii, Masaya Takahashi, Takahiro Arai, Yasushi Murachi, Yumiko Sato, Takahiro Mikami, Koji Hashiguchi, Tomoko Yamazaki, Katsuyuki Takahashi, Yukiyoshi Fujita, Yuki Hosokawa, Issei Morozumi, Masami Tsuchiya, Atsushi Yokoyama, Hironobu Hashimoto, Masakazu Yamaguchi

Scientific reports 12 ( 1 ) 6561 - 6561 2022.04

ISSN 2045-2322

The association between capecitabine efficacy and proton pump inhibitors (PPIs) is controversial. Here, we determined whether co-administration of PPIs affects the real-world effectiveness of capecitabine. This retrospective observational study included consecutive patients with stage II-III colorectal cancer (CRC) who received adjuvant capecitabine monotherapy or CapeOX (capecitabine and oxaliplatin) between January 2009 and December 2014 at nine participating institutions. The primary endpoint was the difference in relapse-free survival (RFS) between patients who received PPIs and those who did not and was estimated using the Kaplan-Meier method. Overall survival (OS) was the secondary endpoint. Multivariable analysis of RFS and OS was performed using a Cox proportional hazards model, propensity score adjustment, and inverse probability of treatment weighting (IPTW) analyses. Data from 606 patients were evaluated, 54 of whom had received a PPI. PPI-treated patients tended to have poorer RFS and OS than patients treated without PPIs. The hazard ratio for RFS with capecitabine monotherapy was 2.48 (95% confidence interval: 1.22-5.07). These results were consistent with sensitivity analyses performed using propensity score adjustment and IPTW methods. Co-administration of PPIs may reduce the effectiveness of capecitabine and negatively impact patients with stage II-III CRC.

Access to Document (DOI)

　 Previous page - Next page 　